Citigroup
OBIO icon

Citigroup’s Orchestra BioMed OBIO Stock Holding History

Citigroup’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$108K Buy
25,529
+6,071
+31% +$25.8K ﹤0.01% 4250
2025
Q4 		$80.8K Buy
19,458
+19,417
+47,359% +$78.3K ﹤0.01% 4409
2025
Q3 		$102 Sell
41
-7,620
-99% -$21K ﹤0.01% 5809
2025
Q2 		$20.5K Sell
7,661
-9,557
-56% -$27.9K ﹤0.01% 5067
2025
Q1 		$73.7K Sell
17,218
-2,029
-11% -$10.1K ﹤0.01% 4752
2024
Q4 		$77K Buy
19,247
+2,397
+14% +$12.9K ﹤0.01% 4946
2024
Q3 		$86.6K Buy
16,850
+11,698
+227% +$76.4K ﹤0.01% 4824
2024
Q2 		$42K Buy
5,152
+2,749
+114% +$15.9K ﹤0.01% 4688
2024
Q1 		$12.7K Buy
2,403
+332
+16% +$2.25K ﹤0.01% 5150
2023
Q4 		$18.9K Buy
2,071
+2,069
+103,450% +$14.1K ﹤0.01% 5010
2023
Q3 		$17 Sell
2
-1,562
-100% -$10.5K ﹤0.01% 5590
2023
Q2 		$10.9K Buy
+1,564
New +$23.7K ﹤0.01% 5054

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Citigroup's OBIO Position: Q1 2026 in Review

Citigroup increased its Orchestra BioMed (OBIO) stake by 31% in Q1 2026, buying an estimated $25.8K and bringing the position to 25,529 shares worth $108K. The position accounts for ﹤0.01% of the portfolio, ranked #4250.

Citigroup first reported a position in OBIO in Q2 2023 and has held it in 12 quarters since. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

  • Citigroup held 25,529 shares of Orchestra BioMed worth $108K as of Q1 2026.
  • Citigroup bought 6,071 Orchestra BioMed shares in Q1 2026, an estimated $25.8K.
  • Orchestra BioMed made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4250 holding.
  • Citigroup first reported a position in Orchestra BioMed in Q2 2023 and has held it in 12 quarters since.
  • 65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.